Today: 9 June 2026
Salesforce stock wobbles after hours as Slackbot AI-agent rollout meets fresh software-sector nerves

Salesforce stock wobbles after hours as Slackbot AI-agent rollout meets fresh software-sector nerves

New York, Jan 14, 2026, 18:04 EST — After-hours

  • Salesforce shares dipped once more as investors digested the implications of AI agents for major subscription software.
  • The company is launching a redesigned Slackbot within Slack, promoting it as a “personal agent for work.”
  • Traders want proof that AI features boost revenue, not just increase expenses or reduce software “seats.”

Salesforce (CRM) shares dipped 0.6% during Wednesday’s regular session, trading near $239.57 in after-hours. The stock followed a broader selloff in big enterprise software names. Oracle slumped 4.3%, while ServiceNow dropped 2.6% by the close, according to MarketWatch data.

The small pullback came after Tuesday’s sharp selloff, when Salesforce plunged 6.5% as investors fretted that AI-driven productivity gains might shrink software subscriptions in the long run. Adobe took a hit that day as well, following an Oppenheimer downgrade. The takeaway was clear: AI features are real, but turning them into steady revenue remains a tough challenge.

Salesforce’s newest product launch arrives amid a tricky market environment. On Tuesday, the company announced the general availability of a revamped Slackbot for select Business+ and Enterprise+ clients, with the rollout set to continue in phases through January and February. “It’s the front door to the Agentic Enterprise,” said Slack CTO Parker Harris in the release. Salesforce Investor Relations

TechCrunch revealed that the updated Slackbot can locate information, draft emails, and set up meetings within Slack. If users allow it, the bot also links to tools like Microsoft Teams and Google Drive. Harris told TechCrunch the name Slackbot stuck because it’s already widely recognized.

The timing isn’t random. A fresh surge of “agentic” tools — software that carries out a series of actions for users — has reignited the debate over whether apps lose their stickiness when work happens through a chat-style interface. Anthropic rolled out “Claude Cowork” this week, a research preview capable of accessing folders and running tasks within its macOS app, according to The Verge. The Verge

On Wall Street, some analysts say the gloom is outpacing the facts. Barclays’ Raimo Lenschow bumped his price target on Salesforce to $338 from $330 and maintained an Overweight rating. He noted that “Macro and IT spending are stable,” and pointed out that “stock valuation levels are low and the sector is out of favor,” according to a report from TheFly, cited by TipRanks. TipRanks

A separate filing revealed that CEO Marc Benioff exercised a stock option for a single share at $215.17 on Jan. 13. Though the trade was minor, it caught attention amid a market quick to dissect insider moves and investor sentiment.

The risk scenario remains. If AI agents cut down the demand for per-user “seat” licenses—the usual subscription model charging by headcount—revenue growth might stall, even with strong customer interest. And if these AI add-ons don’t prove their value quickly, CIOs may just hold off.

Wednesday’s wider market dragged, with U.S. stocks sliding for a second straight day. Investors wrestled with mixed results from major banks alongside fresh economic figures, Reuters reported, feeding uneven risk appetite beyond just the software sector.

Investors are looking for early clues on whether the Slackbot rollout will boost paid adoption of Salesforce’s AI offerings, rather than just serving as a Slack feature update. Salesforce said enterprise admins can manage Slackbot access permissions through Feb. 10, a key date to gauge customer uptake. The company hasn’t announced its next earnings release yet, but MarketBeat projects the report will arrive on Feb. 25.

Stock Market Today

  • NSE Allocates 10% of Annual CSR Fund to Social Stock Exchange
    June 9, 2026, 10:16 AM EDT. The National Stock Exchange (NSE) will deploy 10% of its annual Corporate Social Responsibility (CSR) corpus through the Social Stock Exchange, signaling trust in this market-based platform designed to connect social enterprises with investors. This move aims to enhance transparency and impact investing by leveraging the exchange's resources to support social causes.

Latest articles

Regentis Biomaterials Stock: Tiny RGNT Is Back In Focus Before The Bell

Regentis Biomaterials Stock: Tiny RGNT Is Back In Focus Before The Bell

9 June 2026
Regentis Biomaterials shares dipped 2 cents to $1.28 premarket after the company announced European surgeon training for its GelrinC knee implant will begin in Q3, marking a key commercial step but leaving investors waiting for revenue proof as the stock trades far below its $8 IPO price.
IREN Stock Approaches $60 as AI Data-Center Bet Hits Key Point

IREN Stock Approaches $60 as AI Data-Center Bet Hits Key Point

9 June 2026
IREN surged 8.9% to $59.19 and was quoted higher premarket after a bitcoin rebound and renewed focus on its pivot to AI cloud infrastructure, but the stock remains exposed to bitcoin swings, heavy spending, and risks tied to its new 800MW South Australia data center project and major contracts with Nvidia and Microsoft.
AT&T Moves Higher Pre-Market on $45 Billion Payout Plan Still in Focus

AT&T Moves Higher Pre-Market on $45 Billion Payout Plan Still in Focus

9 June 2026
AT&T shares edged up to $22.58 pre-market after reaffirming 2026 guidance and a $45B+ shareholder return plan, providing a cash-flow marker as satellite broadband competition looms; the stock remains pressured by SpaceX risks flagged by Oppenheimer, with second-quarter free cash flow seen at $4.0–$4.5B.
GSK’s $10.6 Billion Oncology Leap Goes Deeper Than Headlines Show

GSK’s $10.6 Billion Oncology Leap Goes Deeper Than Headlines Show

9 June 2026
GSK will buy Nuvalent for $10.6 billion in cash, paying a 40% premium, to boost its oncology pipeline ahead of looming HIV drug patent expiries; Nuvalent shares jumped 38.9% premarket while GSK fell 1.4%, with the deal expected to add to GSK sales and profit from 2027 but dilute earnings per share 2026-2028 if it closes in Q3, and final outcome depends on FDA approvals and regulatory clearance.
Kohl’s stock slides 5% as Jefferies trims target to $22, tariff ruling keeps retailers on edge
Previous Story

Kohl’s stock slides 5% as Jefferies trims target to $22, tariff ruling keeps retailers on edge

Morgan Stanley stock slips before earnings as Wall Street digests big-bank signals
Next Story

Morgan Stanley stock slips before earnings as Wall Street digests big-bank signals

Go toTop